MicroPort NeuroTech Revenue, Valuation, Funding & Investors

MicroPort NeuroTech is valued at $1.8B as of November 2021, a 31.3x multiple on its last reported $56M revenue.

Last MicroPort NeuroTech valuation

$1.8B

Undisclosed stage · Nov 2021

Last MicroPort NeuroTech funding round

$150M

Undisclosed stage · Nov 2021

MicroPort NeuroTech revenue

$56M

Undisclosed stage · Nov 2021

Key investors in MicroPort NeuroTech

  • CICC Healthcare Investment Fund
  • Huayi Capital

MicroPort NeuroTech Overview

About MicroPort NeuroTech

MicroPort NeuroTech is a Shanghai-based neurovascular specialist founded in 2012 that develops stents for cerebrovascular diseases. Its WILLIS Intracranial Stent Graft System treats wide-neck aneurysms, while APOLLO and Tubridge devices reconstruct vessels. The company supplies over 500 hospitals in China with retrievable stents and flow diverters. MicroPort NeuroTech exports to Asia and Europe, focusing on stroke prevention therapies.


Founded

2012

HQ

ChinaShanghai

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Revenue

$56M (Nov 2021)

Valuation

$1.8B (Nov 2021)

MicroPort NeuroTech Valuation

MicroPort NeuroTech is currently valued at $1.8B, based on its undisclosed-stage round in November 2021.

The $150M round included Huayi Capital and CICC Healthcare Investment Fund.

MicroPort NeuroTech valuation by funding round

MicroPort NeuroTech valuation by funding round
DateStageValuationRevenue Multiple
Nov 2021Undisclosed stage$1.8B31.3x

MicroPort NeuroTech Revenue

MicroPort NeuroTech's latest recorded revenue is $56M, as of its undisclosed-stage round in November 2021. At a $1.8B valuation, that implies a 31.3x revenue multiple.

MicroPort NeuroTech revenue by funding round

MicroPort NeuroTech revenue and valuation multiple by funding round
DateRevenue *ValuationRevenue MultipleStage
Nov 2021$56M$1.8B31.3xUndisclosed stage

* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.

MicroPort NeuroTech Funding History

MicroPort NeuroTech has raised a total of $150M across 1 funding round.

MicroPort NeuroTech funding rounds

MicroPort NeuroTech funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Nov 2021Undisclosed stageHuayi Capital; CICC Healthcare Investment Fund$150M$1.8BMicroPort NeuroTech Limited (also referred to as Minimally Invasive Brain Science™ or MicroPort NeuroTech), a subsidiary of MicroPort Scientific Corporation (00853.HK), is a leading Chinese company in the neurointerventional medical device industry, focusing on innovative solutions for cerebrovascular diseases. It is the top Chinese player and among the top 5 globally, with 5 CE Markings, products in 18 overseas countries, and FDA, CE, and MDFS approved commercialized products. The company completed a US$150 million equity financing round on November 11, 2021, introducing strategic investors including CICC Capital (CICC Healthcare Investment Fund), Huayi Capital, Bohua Capital, Runkun Tianlu, and Tongxin Investment. The post-money valuation reached approximately $1.75 billion USD (equivalent to 11.2 billion yuan), positioning it as a leader in neurointervention market capitalization. This round followed prior convertible bonds subscribed by Belin Capital for $70 million. MicroPort NeuroTech maintains strong profitability in its neurovascular devices business, with group-level neurovascular revenue at $59.1 million in 2021, up 72.5% year-over-year, though specific revenue for NeuroTech alone is not broken out separately. The financing supports ongoing innovation, including an HKEx IPO application in progress at the time. MicroPort NeuroTech has a portfolio of 30 commercialized products and candidates since its first approval in 2004. The parent company's neurovascular segment showed rapid growth driven by market penetration and new launches, benefiting from normalization of surgeries post-epidemic.

Who has invested in MicroPort NeuroTech?

2 investors have backed MicroPort NeuroTech across its funding rounds, including CICC Healthcare Investment Fund and Huayi Capital.


MicroPort NeuroTech Investors

Investors in MicroPort NeuroTech by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 2 MicroPort NeuroTech investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

MicroPort NeuroTech Competitors

MicroPort NeuroTech competitors include listed companies like Jafron Biomedical, Poly Medicure, Qingdao Baheal Medical and Immunocore Holdings, and private ones like Rakuten Medical and Meril Life.

Public and private companies comparable to MicroPort NeuroTech
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Jafron BiomedicalChinaChinaPublicly listed$300M$123M$1.8B5.2x
Rakuten MedicalUnited StatesSan Diego, CAPrivate--$1.7B-
Meril LifeIndiaVapiPrivate--$1.8B-
Poly MedicureIndiaIndiaPublicly listed$196M$59M$1.8B8.1x
Qingdao Baheal MedicalChinaChinaPublicly listed$1.1B$139M$1.8B1.9x
Immunocore HoldingsUnited StatesUnited StatesPublicly listed$400M($20M)$1.7B2.8x

MicroPort NeuroTech Public Comps

MicroPort NeuroTech is still privately-owned, but its public comps include SKAN Group, Cofoe Medical, Embla Medical, Jafron Biomedical, Poly Medicure, Qingdao Baheal Medical, Edge Medical, LeMaitre Vascular, Immunocore Holdings and Mehow Innovative.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SKAN Group$406M$43M4.5x3.9x42.0x28.5x
Cofoe Medical$505M$89M2.9x2.4x16.2x15.0x
Embla Medical$929M$187M2.4x2.2x11.9x10.9x
Jafron Biomedical$300M$123M5.4x5.2x13.2x11.2x
Poly Medicure$196M$59M9.0x8.1x30.1x33.2x
Qingdao Baheal Medical$1.1B$139M1.9x1.9x15.1x16.8x
Edge Medical$68M($10M)22.9x14.3x(153.6x)241.6x
LeMaitre Vascular$250M$91M6.5x6.1x18.0x19.5x

This data is available for Pro users. Sign up to see all MicroPort NeuroTech competitors and their valuation data.

Start Free Trial

Common questions about MicroPort NeuroTech

When was MicroPort NeuroTech founded?MicroPort NeuroTech was founded in 2012.
Where is MicroPort NeuroTech headquartered?MicroPort NeuroTech is headquartered in Shanghai, China.
Is MicroPort NeuroTech publicly listed?No, MicroPort NeuroTech is a private, VC-backed company.
What is MicroPort NeuroTech's valuation?MicroPort NeuroTech was last valued at $1.8B in its undisclosed-stage round in November 2021.
How much funding has MicroPort NeuroTech raised?MicroPort NeuroTech has raised $150M across 1 funding round.
What was MicroPort NeuroTech's last funding round?MicroPort NeuroTech's last funding round was a $150M undisclosed-stage round in November 2021.
Who are MicroPort NeuroTech's investors?MicroPort NeuroTech's investors include Huayi Capital and CICC Healthcare Investment Fund.
What is MicroPort NeuroTech's revenue?MicroPort NeuroTech's latest recorded revenue is $56M (November 2021).
What is MicroPort NeuroTech's revenue multiple?MicroPort NeuroTech's latest valuation implies a 31.3x revenue multiple ($1.8B valuation on $56M of revenue).
Which companies are comparable to MicroPort NeuroTech?Companies comparable to MicroPort NeuroTech include Jafron Biomedical, Rakuten Medical, Meril Life, Poly Medicure, Qingdao Baheal Medical and Immunocore Holdings.

See companies similar to MicroPort NeuroTech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial